tocilizumab: Clinical Trials

61 trials of tocilizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 14 unknown, 7 terminated, 6 recruiting. 61 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 461Completed 31, Unknown 14, Terminated 7, Recruiting 6, Withdrawn 2, Not yet recruiting 1

Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment Strategy for Patients With RA-ILD
Tocilizumab, Rituximab (RTX), Methotrexate - Rheumatoid Arthritis Associated Interstitial Lung Disease
Phase 4Not yet recruitingChinese SLE Treatment And Research Group2042026-09-202026-09-03
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 4RecruitingRegeneron Pharmaceuticals302026-07-152026-10-27
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg) - Thyroid-Associated Ophthalmopathy
Phase 4RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University602024-12-122025-04-16
Plan Development for Giving Teclistamab in the Outpatient Setting
Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer
Phase 4RecruitingUniversity Health Network, Toronto152024-11-192025-12-10
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
Dexamethasone, Tocilizumab, Anakinra - Sepsis, Neuroinflammatory Response
Phase 4UnknownRadboud University Medical Center522024-10-242025-04-04
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
Prednisone, Methotrexate, Tocilizumab - Takayasu Arteritis
Phase 4RecruitingShanghai Zhongshan Hospital1242024-06-282024-10-17
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Nivolumab, Pembrolizumab, Ipilimumab - Oncology, Infusion Reaction
Phase 4RecruitingIsala10822023-09-012026-10-29
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First - Heart Failure
Phase 4CompletedBrigham and Women's Hospital5032023-05-052026-02-06
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
Tocilizumab - Multiple Myeloma
Phase 4UnknownThe First Affiliated Hospital of Soochow University482023-04-172023-06-02
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin - Cancer Therapy-related Cardiovascular Toxicity
Phase 4UnknownPeking University Third Hospital2002023-02-152023-02-16
Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)
Methylprednisolone, intravenous immunoglobulin, Tocilizumab - Severe Fever With Thrombocytopenia Syndrome
Phase 4UnknownQin Ning3502022-08-192023-07-21
High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
Methylprednisolone, Tocilizumab - COVID-19 Virus Infection, Cytokine Storm
Phase 4WithdrawnMarmara University2021-02-012021-11-24
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia
Phase 4UnknownOctober 6 University1502020-10-012021-03-17
A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
Tocilizumab, Glucocorticoids - Idiopathic Retroperitoneal Fibrosis
Phase 4UnknownPeking Union Medical College Hospital402020-07-012021-03-22
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Tocilizumab - Covid19
Phase 4CompletedFMH College of Medicine and Dentistry932020-05-122021-01-29
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Tocilizumab - Covid19 Pneumonia
Phase 4UnknownHadassah Medical Organization5002020-04-082020-05-06
A Pilot Study in Severe Patients With Takayasu Arteritis.
Tocilizumab, Adalimumab - Takayasu Arteritis, Tocilizumab
Phase 4RecruitingShanghai Zhongshan Hospital402020-03-012021-08-10
Use of Tocilizumab Drug Levels to Optimize Treatment in RA
Tocilizumab - Rheumatoid Arthritis
Phase 4UnknownReade Rheumatology Research Institute982020-03-012024-04-18
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
tacrolimus, methotrexate, adalimumab - Rheumatoid Arthritis (RA)
Phase 4CompletedAstellas Pharma Korea, Inc.212019-02-132024-10-31
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis
Tocilizumab - Rheumatoid Arthritis, Tocilizumab
Phase 4UnknownTel-Aviv Sourasky Medical Center802018-12-012018-12-26

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Arthritis, Rheumatoid (37)  ·  COVID-19 (3)  ·  Cytokine Release Syndrome (3)  ·  Multiple Myeloma (3)  ·  Arthritis, Juvenile (2)  ·  Giant Cell Arteritis (2)  ·  Neoplasms (2)  ·  Takayasu Arteritis (2)  ·  Aortitis (1)  ·  Arthritis (1)  ·  Endotoxemia (1)  ·  Graves Ophthalmopathy (1)  ·  Heart Failure (1)  ·  Neuroinflammatory Diseases (1)  ·  Plaque, Atherosclerotic (1)

Sponsors

Hoffmann-La Roche (21)  ·  Karolinska Institutet (2)  ·  Massachusetts General Hospital (2)  ·  Shanghai Zhongshan Hospital (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Astellas Pharma Korea, Inc. (1)  ·  Brigham and Women's Hospital (1)  ·  Centre Hospitalier Régional d'Orléans (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Chinese PLA General Hospital (1)  ·  Chinese SLE Treatment And Research Group (1)  ·  Dr. Larry W. Moreland (1)  ·  FMH College of Medicine and Dentistry (1)  ·  Genentech, Inc. (1)  ·  Hadassah Medical Organization (1)

Countries

United States (12)  ·  China (9)  ·  France (8)  ·  United Kingdom (7)  ·  Italy (6)  ·  Netherlands (6)  ·  Spain (6)  ·  Germany (5)  ·  Israel (5)  ·  Russia (5)  ·  Finland (4)  ·  Sweden (4)  ·  Belgium (3)  ·  Canada (3)  ·  Greece (3)

Top investigators

Lindi Jiang, PhD (2)  ·  Ronald van Vollenhoven, MD, Prof. (2)  ·  Ahmed Tawakol, MD (1)  ·  Aijaz Zeeshan Khan Chachar, MBBS,FCPS (1)  ·  Ana D Fernandes, MA (1)  ·  Christian Dejaco, MD, PhD (1)  ·  Christine Chen, Dr. (1)  ·  Dr Maya H Buch (1)  ·  Eric Toussirot, Professor (1)  ·  Gertjan Wolbink, MD, PhD (1)

Results publications

PMID 28376912, PMID 14558057, PMID 22674883, PMID 23515142, PMID 24448345, PMID 25167216, PMID 25697557, PMID 26613768, PMID 26733110, PMID 27654603, PMID 28955499, PMID 29853455, PMID 29884223, PMID 31043095, PMID 31106666, PMID 31413865, PMID 31469238, PMID 32025629, PMID 32212002, PMID 32711802, PMID 32803573, PMID 32993784, PMID 33268527, PMID 33585031, PMID 34256800, PMID 34269927, PMID 34764044, PMID 36828925, PMID 37423647, PMID 37540159, PMID 37846618, PMID 37942714, PMID 38251564, PMID 38580350, PMID 39079894, PMID 40480650, PMID 40527572, PMID 41652651, PMID 41881637, PMID 41943506, PMID 42567558

NIH funding

2009 (3), 2014 (2), 2018 (1), 2023 (1)